PRINCETON, N.J. --(BUSINESS WIRE)--Dec. 20, 2019-- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announces its financial results for the fiscal year ended October 31, 2019 and provides a business

Cash balance anticipated to extend into 2021 "At Advaxis, we are committed to unlocking the potential benefits of our Lm TechnologyTM platform to improve outcomes for cancer patients" PRINCETON, N.J.--( BUSINESS WIRE )--Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on

PRINCETON, N.J.--( BUSINESS WIRE )--Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced a research collaboration agreement with the University of California Los Angeles (UCLA) to

Median overall survival for ADXS-PSA in combination with KEYTRUDA   ®   increased to 33.6 months from previously reported 21.1 months "We are excited to report these updated data which show a meaningful increase in median overall survival for patients in the combination arm of the KEYNOTE-046

"Safety and Immunogenicity of a Personalized Neoantigen-Listeria Vaccine in Cancer Patients" PRINCETON, N.J.--( BUSINESS WIRE )--Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today

PRINCETON, N.J.--( BUSINESS WIRE )--Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that its chief executive officer, Kenneth A. Berlin, issued an open letter to Advaxis’

PRINCETON, N.J.--( BUSINESS WIRE )-- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”) , a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced the closing of its previously announced underwritten public offering of

PRINCETON, N.J.--( BUSINESS WIRE )-- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”) , a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced the pricing of an underwritten public offering of (i) 9,200,000 shares of

CD8+ T Cell Reactivity Against 90% of Personalized Neoantigen Targets Confirmed in First of Two Patients Proof-of-Mechanism for Off-the-Shelf ADXS-HOT Program with CD8+ T Cells Against Hotspot Mutations Antigen Spreading Confirmed PRINCETON, N.J.--( BUSINESS WIRE )-- Advaxis, Inc.

"We remain firmly committed to our Lm Technology™ platform, including our personalized and off-the-shelf approaches for neoantigen-directed therapies, and the development of AXAL against HPV-related cancers" PRINCETON, N.J.--( BUSINESS WIRE )-- Advaxis, Inc.